Natalie Arnold/LinkedIn
Jan 25, 2026, 12:17
Natalie Arnold on 11 Clinical Trials That Will Shape Medicine in 2026
Natalie Arnold, Preventive Cardiologist at University Heart and Vascular Center Hamburg, shared on LinkedIn:
”“What does the coming day hold (for me)?”
(AS Pushkin, Eugene Onegin)
Nature Medicine recently spotlighted 11 clinical trials that may shape medicine in 2026.
Two of them align directly with my research focus in cardiovascular prevention:
• Low-grade inflammation: IL-6 inhibition with ziltivekimab
• Lipoprotein (a): pelacarsen for patients with elevated Lp(a)
2026 may be a key year for turning “residual risk” biology into therapies that improve clinical outcomes.”
Read the full article here.
Article: Eleven clinical trials that will shape medicine in 2026
Author: Mike May
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 21, 2026, 21:07Tareq Abadl: Not Every Low Platelet Count Is True – Check the Smear First
-
Apr 21, 2026, 21:05Beverley Hunt: Honored to Receive the Lifetime Achievement Award at BSH 2026
-
Apr 21, 2026, 21:03Toong Youttananukorn: Proud to Support Data That Drives Action at WFH 2026
-
Apr 21, 2026, 20:48Ney Carter Borges: Endothelial Senescence as a Central Driver of Adipose Dysfunction in Heart Failure and Type 2 Diabetes
-
Apr 21, 2026, 20:29Can Stem Cell-Delivered Platelets Fight Drug-Resistant Bacteria?- RPTH Journal
-
Apr 21, 2026, 18:51WHO Expert Lorenzo Moja Discusses How Essential Medicines Policy Expands Access to Treatment – WFH
-
Apr 21, 2026, 18:35Ana Pedrero Gil: New ASH–ISTH 2026 Guidelines Focus on Preventing VTE in Children
-
Apr 21, 2026, 17:36Sip Wijchers: Is It Time to Use Ultrasound for Every AF Ablation Access?
-
Apr 21, 2026, 16:32Sarah Walbolt։ Have You Ever Wondered What Actually Happens to Your Donated Blood?